ClinicalTrials.gg
TerminatedNCT06453668AURORAUpdated Jul 17, 2026

A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients

A Phase 1 interventional study of TCD601 in ALS, sponsored by ITB-Med LLC. Terminated at 3 sites in Sweden. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by ITB-Med LLC · Phase 1, Interventional, and Basic science

Why this study was terminated
The Sponsor has decided to terminate study early due to significant enrolment challenges since restarting the study in Dec 2025. The Sponsor is concerned that the study is not feasible and ultimately the objectives of the study cannot be met.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Amyotrophic Lateral Sclerosis with a site in Sweden — 6 open to participants now, 11 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Sweden.

Enrollment
34th of 34
7 · median 234
Started
2024
with 4 others
Phase 1
Only one
of the 34
Registered
29th of 34
by date

Among the 34 studies in Amyotrophic Lateral Sclerosis with a site in Sweden, this one is the 34th largest by enrollment, is one of 5 that started in 2024, is the only one in phase 1, and was the 29th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

6 of the 34 studies in Amyotrophic Lateral Sclerosis with a site in Sweden are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Amyotrophic Lateral Sclerosis with a site in Sweden, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TCD601 (siplizumab) in newly diagnosed adult ALS patients.

Read the detailed description

The purpose of this study is to investigate how safe and tolerable the study drug siplizumab is when given to adult patients with ALS. The study will examine how the drug is distributed in the body and what effects it has on different immune cells in the blood and in the fluid surrounding the motor neurons (cerebrospinal fluid). In addition, the study will monitor the progression of ALS and look for any changes related to the disease that may occur during the study.

03

Conditions studied

  • ALS

Keywords

  • Amyotrophic Lateral Sclerosis
  • Neuroinflammatory
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Male or female patients ≥ 18 to 80 years of age.
  • Diagnosis of ALS by revised El Escorial Criteria, at study entry within 24 months of first symptoms.
  • Patients on existing ALS treatment must have been on a stable dose for 28 days.

Key Exclusion Criteria:

  • Patient with severe systemic infections, current or within the two weeks prior to randomization.
  • Subjects who, in the opinion of the investigator, are not capable of giving for the study or who are unable or unwilling to adhere to the study requirements outlined in the protocol.
  • Use of other products or treatment in another investigational drug study within 30 days of screening
  • Pregnant or nursing (lactating) women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Treatment

    TCD601 (siplizumab) administered with the contemporary standard of care regimen.

    Biological: TCD601

Interventions

  • BiologicalTCD601

    Investigational Product

    Also known as: siplizumab

06

What researchers measure

Primary outcomes

  1. Evaluation of the safety of TCD601 in adult patients with ALS

    Assess the incidence of treatment-emergent Adverse Events \[Safety and Tolerability\]

    Time frame: 12 Months

Secondary outcomes

  1. Evaluation of the pharmacokinetics (PK)

    Siplizumab concentration over time

    Time frame: 12 Months

  2. Correlation of ALS disease status with leucocyte phenotypic profiles

    The ALS disease status measured by ALSFRS and Kings staging will be compared with the leucocyte phenotypes measured by FACS analysis.

    Time frame: 12 Months

  3. Evaluation of levels of biomarkers

    Neurofilament light chain levels over time

    Time frame: 12 Months

  4. Length of time from trial entry to tracheostomy / death

    The time from study enrollment to patient death or tracheostomy will be measured.

    Time frame: 12 Months

  5. Assessment of clinically relevant changes in laboratory measurements

    Incidence of abnormal laboratory values

    Time frame: 12 Months

  6. Evaluation of pharmacodynamics (PD) of TCD601

    Lymphocyte counts by subset over time

    Time frame: 12 Months

  7. Assessment of clinically relevant changes in vital signs

    Incidence of abnormal vital signs

    Time frame: 12 Months

07

Study locations

3 sites
  • Skåne University Hospital Malmö
    Malmö, 205 02, Sweden
  • Studieenheten Akademiskt Specialistcentrum
    Stockholm, 171 77, Sweden
  • Umeå University Hospital
    Umeå, 901 85, Sweden
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Jul 2026, 26 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2024
First posted
Jun 12, 2024
StartActual
Apr 16, 2024
Primary completionActual
Jul 2, 2026
CompletionActual
Jul 2, 2026
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06453668
Lead sponsor
ITB-Med LLC
Responsible party
Sponsor
First posted
Jun 12, 2024
Start date
Apr 16, 2024
Primary completion
Jul 2, 2026
Completion
Jul 2, 2026
Last update
Jul 17, 2026

Study contacts

Fredrik Julin
study director · ITB-Med LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion